PEPGEN INC. Comprehensive Income
PEPGEN INC. (PEPG) reported Comprehensive Income of -$17.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$17.87M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$17.83M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$18.30M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$18.01M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$89.67M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$89.99M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$78.51M.
- PEPGEN INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$69.20M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.87M 10-Q · filed 2026-08-06 | -$35.70M 10-Q · filed 2026-08-06 | -$54.01M derived: sum of 3 quarters · filed 2026-08-06 | -$72.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$17.83M 10-Q · filed 2026-05-12 | -$36.14M derived: sum of 2 quarters · filed 2026-05-12 | -$54.15M derived: sum of 3 quarters · filed 2026-05-12 | -$77.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$18.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$36.31M derived: sum of 2 quarters · filed 2026-03-04 | -$59.42M derived: sum of 3 quarters · filed 2026-08-06 | -$89.67M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$18.01M 10-Q · filed 2025-11-12 | -$41.12M derived: sum of 2 quarters · filed 2026-08-06 | -$71.36M 10-Q · filed 2025-11-12 | -$93.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$23.11M 10-Q · filed 2026-08-06 | -$53.35M 10-Q · filed 2026-08-06 | -$75.67M derived: sum of 3 quarters · filed 2026-08-06 | -$96.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$30.25M 10-Q · filed 2026-05-12 | -$52.56M derived: sum of 2 quarters · filed 2026-05-12 | -$73.78M derived: sum of 3 quarters · filed 2026-05-12 | -$102.15M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$22.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$43.53M derived: sum of 2 quarters · filed 2026-03-04 | -$71.90M derived: sum of 3 quarters · filed 2026-03-04 | -$89.99M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$21.22M 10-Q · filed 2025-11-12 | -$49.59M derived: sum of 2 quarters · filed 2025-11-12 | -$67.68M 10-Q · filed 2025-11-12 | -$87.09M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$28.37M 10-Q · filed 2025-08-07 | -$46.46M 10-Q · filed 2025-08-07 | -$65.87M derived: sum of 3 quarters · filed 2025-08-07 | -$89.23M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$18.09M 10-Q · filed 2025-05-08 | -$37.49M derived: sum of 2 quarters · filed 2025-05-08 | -$60.85M derived: sum of 3 quarters · filed 2025-05-08 | -$80.34M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$19.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$42.76M derived: sum of 2 quarters · filed 2025-02-24 | -$62.24M derived: sum of 3 quarters · filed 2025-02-24 | -$78.51M 10-K · filed 2025-02-24 |
| 2023-09-30 | -$23.36M 10-Q · filed 2024-11-07 | -$42.84M derived: sum of 2 quarters · filed 2024-11-07 | -$59.11M 10-Q · filed 2024-11-07 | -$73.99M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$19.48M 10-Q · filed 2024-08-08 | -$35.75M 10-Q · filed 2024-08-08 | -$50.63M derived: sum of 3 quarters · filed 2024-08-08 | -$69.27M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$16.27M 10-Q · filed 2024-05-14 | -$31.15M derived: sum of 2 quarters · filed 2024-05-14 | -$49.79M derived: sum of 3 quarters · filed 2024-05-14 | -$67.15M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$14.89M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$33.52M derived: sum of 2 quarters · filed 2024-03-29 | -$50.88M derived: sum of 3 quarters · filed 2024-03-29 | -$69.20M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | -$18.64M 10-Q · filed 2023-11-08 | -$35.99M derived: sum of 2 quarters · filed 2023-11-08 | -$54.31M 10-Q · filed 2023-11-08 | -$61.46M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$17.36M 10-Q · filed 2023-08-08 | -$35.68M 10-Q · filed 2023-08-08 | -$42.82M derived: sum of 3 quarters · filed 2023-08-08 | -$50.93M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$18.32M 10-Q · filed 2023-05-11 | -$25.46M derived: sum of 2 quarters · filed 2023-05-11 | -$33.57M derived: sum of 3 quarters · filed 2023-05-11 | -$38.97M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$15.25M derived: sum of 2 quarters · filed 2023-03-23 | -$20.65M derived: sum of 3 quarters · filed 2023-03-23 | -$27.26M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$8.11M 10-Q · filed 2022-11-10 | -$13.50M derived: sum of 2 quarters · filed 2022-11-10 | -$20.11M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$5.39M 10-Q · filed 2022-08-12 | -$12.00M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$6.61M 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |